Sequoia Financial Advisors LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 48.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 78,393 shares of the biopharmaceutical company’s stock after purchasing an additional 25,739 shares during the period. Sequoia Financial Advisors LLC’s holdings in Pfizer were worth $2,559,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. State Street Corp grew its position in Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 291,791,099 shares of the biopharmaceutical company’s stock worth $11,432,375,000 after buying an additional 1,521,665 shares during the period. Capital World Investors grew its position in shares of Pfizer by 13.4% in the fourth quarter. Capital World Investors now owns 188,715,390 shares of the biopharmaceutical company’s stock valued at $7,393,867,000 after purchasing an additional 22,232,056 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Pfizer by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 89,043,762 shares of the biopharmaceutical company’s stock valued at $3,482,382,000 after buying an additional 1,630,039 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Pfizer by 4.9% during the fourth quarter. Bank of New York Mellon Corp now owns 59,763,050 shares of the biopharmaceutical company’s stock valued at $2,341,517,000 after buying an additional 2,783,991 shares during the period. Finally, Norges Bank purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $2,326,225,000. 69.91% of the stock is owned by hedge funds and other institutional investors.
Shares of PFE traded up $0.24 during trading hours on Friday, hitting $37.50. The stock had a trading volume of 14,885,114 shares, compared to its average volume of 22,354,300. The company’s fifty day moving average is $36.51 and its two-hundred day moving average is $36.84. The stock has a market capitalization of $206.97 billion, a price-to-earnings ratio of 13.39, a P/E/G ratio of 2.72 and a beta of 0.71. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $44.56.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 8th will be paid a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, May 7th. This represents a $1.52 dividend on an annualized basis and a yield of 4.05%. Pfizer’s payout ratio is 51.53%.
In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of the firm’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $38.35, for a total transaction of $83,641.35. Following the completion of the sale, the senior vice president now owns 9,647 shares of the company’s stock, valued at approximately $369,962.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Douglas M. Lankler sold 65,000 shares of the firm’s stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $37.85, for a total value of $2,460,250.00. Following the sale, the executive vice president now directly owns 135,375 shares of the company’s stock, valued at approximately $5,123,943.75. The disclosure for this sale can be found here. 0.08% of the stock is currently owned by corporate insiders.
A number of research firms have weighed in on PFE. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 price target on shares of Pfizer in a research note on Thursday, March 19th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target for the company. in a report on Monday, May 4th. Mizuho reissued a “buy” rating and set a $42.00 price objective on shares of Pfizer in a report on Monday, May 18th. Standpoint Research raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Finally, Barclays lifted their price target on shares of Pfizer from $36.00 to $37.00 and gave the company an “equal weight” rating in a report on Wednesday, April 29th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $41.28.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: SEC Filing
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.